Celltrion has launched Steqeyma (ustekinumab-stba), its biosimilar of Stelara (ustekinumab), at list price at an 85% discount ...

Celltrion and Formycon with Fresenius Kabi launched their respective ustekinumab biosimilars (Steqeyma and Otulfi), joining 4 ...

UnitedHealth Group stands out as a solid investment choice amidst financial uncertainty. With an equity beta of 0.67, it offers a stable investment with growth potential. The company, driven by ...